Xenova
Executive Summary
Linda Fellows, formerly had of biochemistry section at Britain's Royal Botanical Gardens at Kew, joins in new position of program head of phytopharmaceuticals. At Kew, Fellows conducted research that resulted in the discovery of the anti-HIV effects of n-butyl-deoxynojirimycin, a plant alkaloid derivative that is currently in clinical trials. U.K.-based Xenova, which focuses on small molecule therapeutics that are microbe-derived, has drug discovery collaborators including Genentech, Warner-Lambert, Genzyme and Suntory.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth